Macrophages in multiple myeloma: emerging concepts and therapeutic implications

References

• Kuehl WM, Bergsagel PL. Molecular pathogenesis of multiple myeloma and its premalignant precursor. J Clin Invest 2012;122: 3456–3463.
   PubMed Web of Science ®Google Scholar
• Palumbo A, Anderson K. Multiple myeloma. N Engl J Med 2011;364:1046–1060.
   PubMed Web of Science ®Google Scholar
• Kyle RA, Therneau TM, Rajkumar SV, et al. Prevalence of monoclonal gammopathy of undetermined significance. N Engl J Med 2006;354:1362–1369.
   PubMed Web of Science ®Google Scholar
• Rajkumar SV. Treatment of multiple myeloma. Nat Rev Clin Oncol 2011;8:479–491.
   PubMed Web of Science ®Google Scholar
• Lemaire M, Deleu S, De Bruyne E, et al. The microenvironment and molecular biology of the multiple myeloma tumor. Adv Cancer Res 2011;110:19–42.
   PubMed Web of Science ®Google Scholar
• Roodman GD. Targeting the bone microenvironment in multiple myeloma. J Bone Miner Metab 2010;28:244–250.
   PubMed Web of Science ®Google Scholar
• Mitsiades CS, McMillin DW, Klippel S, et al. The role of the bone marrow microenvironment in the pathophysiology of myeloma and its significance in the development of more effective therapies. Hematol Oncol Clin North Am 2007;21:1007–1034, vii–viii.
   PubMed Web of Science ®Google Scholar
• Hebron E, Hope C, Kim J, et al. MAP3K8 kinase regulates myeloma growth by cell-autonomous and non-autonomous mechanisms involving myeloma-associated monocytes/macrophages. Br J Haematol2012 Dec 18. [Epub ahead of print]
   Google Scholar
• Groen RW, Noort WA, Raymakers RA, et al. Reconstructing the human hematopoietic niche in immunodeficient mice: opportunities for studying primary multiple myeloma. Blood 2012;120: e9–e16.
   PubMed Web of Science ®Google Scholar
• Basak GW, Srivastava AS, Malhotra R, et al. Multiple myeloma bone marrow niche. Curr Pharm Biotechnol 2009;10:345–346.
   PubMed Web of Science ®Google Scholar
• Nair JR, Rozanski CH, Lee KP. Under one roof: the bone marrow survival niche for multiple myeloma and normal plasma cells. Oncoimmunology 2012;1:388–389.
   PubMed Web of Science ®Google Scholar
• Zipori D. The hemopoietic stem cell niche versus the microenvironment of the multiple myeloma-tumor initiating cell. Cancer Microenviron 2010;3:15–28.
   PubMedGoogle Scholar
• Abe M. Targeting the interplay between myeloma cells and the bone marrow microenvironment in myeloma. Int J Hematol 2011;94:334–343.
   PubMed Web of Science ®Google Scholar
• Matsui W, Borrello I, Mitsiades C. Autologous stem cell transplantation and multiple myeloma cancer stem cells. Biol Blood Marrow Transplant 2012;18:S27–S32.
   PubMed Web of Science ®Google Scholar
• Kim D, Park CY, Medeiros BC, et al. CD19(−)CD45(low/−)CD38(high)/CD138(+) plasma cells enrich for human tumorigenic myeloma cells. Leukemia 2012;26:2530–2537.
   PubMed Web of Science ®Google Scholar
• Chanan-Khan AA, Giralt S. Importance of achieving a complete response in multiple myeloma, and the impact of novel agents. J Clin Oncol 2010;28:2612–2624.
   PubMed Web of Science ®Google Scholar
• Hart AJ, Jagasia MH, Kim AS, et al. Minimal residual disease in myeloma: are we there yet?. Biol Blood Marrow Transplant 2012;18:1790–1799.
   PubMed Web of Science ®Google Scholar
• Mantovani A, Sica A. Macrophages, innate immunity and cancer: balance, tolerance, and diversity. Curr Opin Immunol 2010;22: 231–237.
   PubMed Web of Science ®Google Scholar
• Colotta F, Allavena P, Sica A, et al. Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis 2009;30:1073–1081.
   PubMed Web of Science ®Google Scholar
• Qian BZ, Pollard JW. Macrophage diversity enhances tumor progression and metastasis. Cell 2010;141:39–51.
   PubMed Web of Science ®Google Scholar
• Steidl C, Farinha P, Gascoyne RD. Macrophages predict treatment outcome in Hodgkin's lymphoma. Haematologica 2011;96:186–189.
   PubMed Web of Science ®Google Scholar
• Steidl C, Lee T, Shah SP, et al. Tumor-associated macrophages and survival in classic Hodgkin's lymphoma. N Engl J Med 2010;362:875–885.
   PubMed Web of Science ®Google Scholar
• Kamper P, Bendix K, Hamilton-Dutoit S, et al. Tumor-infiltrating macrophages correlate with adverse prognosis and Epstein-Barr virus status in classical Hodgkin's lymphoma. Haematologica 2011;96: 269–276.
   PubMed Web of Science ®Google Scholar
• Farinha P, Masoudi H, Skinnider BF, et al. Analysis of multiple biomarkers shows that lymphoma-associated macrophage (LAM) content is an independent predictor of survival in follicular lymphoma (FL). Blood 2005;106:2169–2174.
   PubMed Web of Science ®Google Scholar
• Byers RJ, Sakhinia E, Joseph P, et al. Clinical quantitation of immune signature in follicular lymphoma by RT-PCR-based gene expression profiling. Blood 2008;111:4764–4770.
   PubMed Web of Science ®Google Scholar
• Hasselblom S, Hansson U, Sigurdardottir M, et al. Expression of CD68 + tumor-associated macrophages in patients with diffuse large B-cell lymphoma and its relation to prognosis. Pathol Int 2008;58: 529–532.
   PubMed Web of Science ®Google Scholar
• Cai QC, Liao H, Lin SX, et al. High expression of tumor-infiltrating macrophages correlates with poor prognosis in patients with diffuse large B-cell lymphoma. Med Oncol 2012;29:2317–2322.
   PubMed Web of Science ®Google Scholar
• Wada N, Zaki MA, Hori Y, et al. Tumour-associated macrophages in diffuse large B-cell lymphoma: a study of the Osaka Lymphoma Study Group. Histopathology 2012;60:313–319.
   PubMed Web of Science ®Google Scholar
• Herreros B, Rodriguez-Pinilla SM, Pajares R, et al. Proliferation centers in chronic lymphocytic leukemia: the niche where NF-kappaB activation takes place. Leukemia 2010;24:872–876.
   PubMed Web of Science ®Google Scholar
• Ramos P, Casu C, Gardenghi S, et al. Removal of macrophages from the erythroid niche impairs stress erythropoiesis but improves pathophysiology of polycythemia vera and beta-thalassemia. Blood 2012;120(Suppl. 1): Abstract 81.
   PubMed Web of Science ®Google Scholar
• Galdiero MR, Garlanda C, Jaillon S, et al. Tumor associated macrophages and neutrophils in tumor progression. J Cell Physiol2012 Oct 12. [Epub ahead of print]
   Google Scholar
• Mantovani A, Germano G, Marchesi F, et al. Cancer-promoting tumor-associated macrophages: new vistas and open questions. Eur J Immunol 2011;41:2522–2525.
   PubMed Web of Science ®Google Scholar
• Pollard JW. Trophic macrophages in development and disease. Nat Rev Immunol 2009;9:259–270.
   PubMed Web of Science ®Google Scholar
• Roussou M, Tasidou A, Dimopoulos MA, et al. Increased expression of macrophage inflammatory protein-1alpha on trephine biopsies correlates with extensive bone disease, increased angiogenesis and advanced stage in newly diagnosed patients with multiple myeloma. Leukemia 2009;23:2177–2181.
   PubMed Web of Science ®Google Scholar
• Peng KW, Dogan A, Vrana J, et al. Tumor-associated macrophages infiltrate plasmacytomas and can serve as cell carriers for oncolytic measles virotherapy of disseminated myeloma. Am J Hematol 2009;84:401–407.
   PubMed Web of Science ®Google Scholar
• Bruns I, Cadeddu RP, Brueckmann I, et al. Multiple myeloma-related deregulation of bone marrow-derived CD34 + hematopoietic stem and progenitor cells. Blood 2012;120:2620–2630.
   PubMed Web of Science ®Google Scholar
• Karin M, Greten FR. NF-kappaB: linking inflammation and immunity to cancer development and progression. Nat Rev Immunol 2005;5:749–759.
   PubMed Web of Science ®Google Scholar
• Gerlo S, Haegeman G, Vanden Berghe W. Transcriptional regulation of autocrine IL-6 expression in multiple myeloma cells. Cell Signal 2008;20:1489–1496.
   PubMedGoogle Scholar
• Abdi J, Engels F, Garssen J, et al. The role of toll-like receptor mediated signalling in the pathogenesis of multiple myeloma. Crit Rev Oncol Hematol 2011;80:225–240.
   PubMed Web of Science ®Google Scholar
• Jourdan M, Tarte K, Legouffe E, et al. Tumor necrosis factor is a survival and proliferation factor for human myeloma cells. Eur Cytokine Netw 1999;10:65–70.
   PubMed Web of Science ®Google Scholar
• Kline M, Donovan K, Wellik L, et al. Cytokine and chemokine profiles in multiple myeloma; significance of stromal interaction and correlation of IL-8 production with disease progression. Leuk Res 2007;31:591–598.
   PubMed Web of Science ®Google Scholar
• Donovan KA, Lacy MQ, Gertz MA, et al. IL-1beta expression in IgM monoclonal gammopathy and its relationship to multiple myeloma. Leukemia 2002;16:382–385.
   PubMed Web of Science ®Google Scholar
• Chiron D, Jego G, Pellat-Deuceunynck C. Toll-like receptors: expression and involvement in multiple myeloma. Leuk Res 2010;34:1545–1550.
   PubMed Web of Science ®Google Scholar
• de Launay D, Vreijling J, Hartkamp LM, et al. Silencing the expression of Ras family GTPase homologues decreases inflammation and joint destruction in experimental arthritis. Am J Pathol 2010;177:3010–3024.
   PubMed Web of Science ®Google Scholar
• Okumura T, Ericksen RE, Takaishi S, et al. K-ras mutation targeted to gastric tissue progenitor cells results in chronic inflammation, an altered microenvironment, and progression to intraepithelial neoplasia. Cancer Res 2010;70:8435–8445.
   Google Scholar
• Lawrence T, Natoli G. Transcriptional regulation of macrophage polarization: enabling diversity with identity. Nat Rev Immunol 2011;11:750–761.
   PubMed Web of Science ®Google Scholar
• Mantovani A, Garlanda C, Allavena P. Molecular pathways and targets in cancer-related inflammation. Ann Med 2010;42:161–170.
   PubMed Web of Science ®Google Scholar
• Pollard JW. Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer 2004;4:71–78.
   PubMed Web of Science ®Google Scholar
• Staudt LM. Oncogenic activation of NF-kappaB. Cold Spring Harb Perspect Biol 2010;2:a000109.
   PubMed Web of Science ®Google Scholar
• Rui L, Schmitz R, Ceribelli M, et al. Malignant pirates of the immune system. Nat Immunol 2011;12:933–940.
   PubMed Web of Science ®Google Scholar
• Keats JJ, Fonseca R, Chesi M, et al. Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma. Cancer Cell 2007;12:131–144.
   PubMed Web of Science ®Google Scholar
• Mahindra A, Hideshima T, Anderson KC. Multiple myeloma: biology of the disease. Blood Rev 2010;24(Suppl. 1):S5–S11.
   PubMed Web of Science ®Google Scholar
• Ehrlich LA, Roodman GD. The role of immune cells and inflammatory cytokines in Paget's disease and multiple myeloma. Immunol Rev 2005;208:252–266.
   PubMed Web of Science ®Google Scholar
• Ivashkiv LB. Inflammatory signaling in macrophages: transitions from acute to tolerant and alternative activation states. Eur J Immunol 2011;41:2477–2481.
   PubMed Web of Science ®Google Scholar
• Kim J, Denu RA, Dollar BA, et al. Macrophages and mesenchymal stromal cells support survival and proliferation of multiple myeloma cells. Br J Haematol 2012;158:336–346.
   PubMed Web of Science ®Google Scholar
• Gocheva V, Joyce JA. Cysteine cathepsins and the cutting edge of cancer invasion. Cell Cycle 2007;6:60–64.
   PubMed Web of Science ®Google Scholar
• Nucera S, Biziato D, De Palma M. The interplay between macrophages and angiogenesis in development, tissue injury and regeneration. Int J Dev Biol 2011;55:495–503.
   Google Scholar
• Rakhmilevich AL, Alderson KL, Sondel PM. T-cell-independent antitumor effects of CD40 ligation. Int Rev Immunol 2012;31:267–278.
   PubMed Web of Science ®Google Scholar
• Rakhmilevich AL, Baldeshwiler MJ, Van De Voort TJ, et al. Tumor-associated myeloid cells can be activated in vitro and in vivo to mediate antitumor effects. Cancer Immunol Immunother 2012;61:1683–1697.
   PubMed Web of Science ®Google Scholar
• Johnson EE, Buhtoiarov IN, Baldeshwiler MJ, et al. Enhanced T-cell-independent antitumor effect of cyclophosphamide combined with anti-CD40 mAb and CpG in mice. J Immunother 2011;34:76–84.
   PubMed Web of Science ®Google Scholar
• Buhtoiarov IN, Sondel PM, Wigginton JM, et al. Anti-tumour synergy of cytotoxic chemotherapy and anti-CD40 plus CpG-ODN immunotherapy through repolarization of tumour-associated macrophages. Immunology 2011;132:226–239.
   Google Scholar
• Wu QL, Buhtoiarov IN, Sondel PM, et al. Tumoricidal effects of activated macrophages in a mouse model of chronic lymphocytic leukemia. J Immunol 2009;182:6771–6778.
   PubMed Web of Science ®Google Scholar
• Buhtoiarov IN, Rakhmilevich AL, Lanier LL, et al. Naive mouse macrophages become activated following recognition of L5178Y lymphoma cells via concurrent ligation of CD40, NKG2D, and CD18 molecules. J Immunol 2009;182:1940–1953.
   PubMed Web of Science ®Google Scholar
• Rakhmilevich AL, Buhtoiarov IN, Malkovsky M, et al. CD40 ligation in vivo can induce T cell independent antitumor effects even against immunogenic tumors. Cancer Immunol Immunother 2008;57:1151–1160.
   PubMed Web of Science ®Google Scholar
• Buhtoiarov IN, Sondel PM, Eickhoff JC, et al. Macrophages are essential for antitumour effects against weakly immunogenic murine tumours induced by class B CpG-oligodeoxynucleotides. Immunology 2007;120:412–423.
   PubMed Web of Science ®Google Scholar
• Lum HD, Buhtoiarov IN, Schmidt BE, et al. Tumoristatic effects of anti-CD40 mAb-activated macrophages involve nitric oxide and tumour necrosis factor-alpha. Immunology 2006;118:261–270.
   PubMed Web of Science ®Google Scholar
• Lum HD, Buhtoiarov IN, Schmidt BE, et al. In vivo CD40 ligation can induce T-cell-independent antitumor effects that involve macrophages. J Leukoc Biol 2006;79:1181–1192.
   PubMed Web of Science ®Google Scholar
• Buhtoiarov IN, Lum HD, Berke G, et al. Synergistic activation of macrophages via CD40 and TLR9 results in T cell independent antitumor effects. J Immunol 2006;176:309–318.
   PubMedGoogle Scholar
• Buhtoiarov IN, Lum H, Berke G, et al. CD40 ligation activates murine macrophages via an IFN-gamma-dependent mechanism resulting in tumor cell destruction in vitro. J Immunol 2005;174: 6013–6022.
   PubMedGoogle Scholar
• Beatty GL, Chiorean EG, Fishman MP, et al. CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science 2011;331:1612–1616.
   PubMed Web of Science ®Google Scholar
• Durie BG, Vela EE, Frutiger Y. Macrophages as an important source of paracrine IL6 in myeloma bone marrow. Curr Top Microbiol Immunol 1990;166:33–36.
   PubMed Web of Science ®Google Scholar
• Babu GR, Jin W, Norman L, et al. Phosphorylation of NF-kappaB1/p105 by oncoprotein kinase Tpl2: implications for a novel mechanism of Tpl2 regulation. Biochim Biophys Acta 2006;1763:174–181.
   PubMed Web of Science ®Google Scholar
• Vougioukalaki M, Kanellis DC, Gkouskou K, et al. Tpl2 kinase signal transduction in inflammation and cancer. Cancer Lett 2011;304:80–89.
   PubMed Web of Science ®Google Scholar
• Waterfield MR, Zhang M, Norman LP, et al. NF-kappaB1/p105 regulates lipopolysaccharide-stimulated MAP kinase signaling by governing the stability and function of the Tpl2 kinase. Mol Cell 2003;11:685–694.
   PubMed Web of Science ®Google Scholar
• Gantke T, Sriskantharajah S, Ley SC. Regulation and function of TPL-2, an IkappaB kinase-regulated MAP kinase kinase kinase. Cell Res 2011;21:131–145.
   PubMed Web of Science ®Google Scholar
• Lawrenz M, Visekruna A, Kuhl A, et al. Genetic and pharmacological targeting of TPL-2 kinase ameliorates experimental colitis: a potential target for the treatment of Crohn's disease?. Mucosal Immunol 2012;5:129–139.
   PubMed Web of Science ®Google Scholar
• Lopez-Pelaez M, Fumagalli S, Sanz C, et al. Cot/tpl2-MKK1/ 2-Erk1/2 controls mTORC1-mediated mRNA translation in Toll-like receptor-activated macrophages. Mol Biol Cell 2012;23:2982–2992.
   PubMed Web of Science ®Google Scholar
• Lopez-Pelaez M, Soria-Castro I, Bosca L, et al. Cot/tpl2 activity is required for TLR-induced activation of the Akt p70 S6k pathway in macrophages: implications for NO synthase 2 expression. Eur J Immunol 2011;41:1733–1741.
   PubMed Web of Science ®Google Scholar
• Mielke LA, Elkins KL, Wei L, et al. Tumor progression locus 2 (Map3k8) is critical for host defense against Listeria monocytogenes and IL-1 beta production. J Immunol 2009;183:7984–7993.
   PubMed Web of Science ®Google Scholar
• Rousseau S, Papoutsopoulou M, Symons A, et al. TPL2-mediated activation of ERK1 and ERK2 regulates the processing of pre-TNF alpha in LPS-stimulated macrophages. J Cell Sci 2008;121:149–154.
   PubMed Web of Science ®Google Scholar
• Zheng Y, Cai Z, Wang S, et al. Macrophages are an abundant component of myeloma microenvironment and protect myeloma cells from chemotherapy drug-induced apoptosis. Blood 2009;114: 3625–3628.
   PubMed Web of Science ®Google Scholar
• Zheng Y, Yang J, Qian J, et al. PSGL-1/selectin and ICAM-1/CD18 interactions are involved in macrophage-induced drug resistance in myeloma. Leukemia2012 Sep 21. [Epub ahead of print]
   Google Scholar
• Yaccoby S, Wezeman MJ, Henderson A, et al. Cancer and the microenvironment: myeloma-osteoclast interactions as a model. Cancer Res 2004;64:2016–2023.
   PubMed Web of Science ®Google Scholar
• Cackowski FC, Anderson JL, Patrene KD, et al. Osteoclasts are important for bone angiogenesis. Blood 2010;115:140–149.
   PubMed Web of Science ®Google Scholar
• Pettit AR, Chang MK, Hume DA, et al. Osteal macrophages: a new twist on coupling during bone dynamics. Bone 2008;43:976–982.
   PubMed Web of Science ®Google Scholar
• Ehninger A, Trumpp A. The bone marrow stem cell niche grows up: mesenchymal stem cells and macrophages move in. J Exp Med 2011;208:421–428.
   PubMed Web of Science ®Google Scholar
• Chang MK, Raggatt LJ, Alexander KA, et al. Osteal tissue macrophages are intercalated throughout human and mouse bone lining tissues and regulate osteoblast function in vitro and in vivo. J Immunol 2008;181:1232–1244.
   PubMed Web of Science ®Google Scholar
• Rajkumar SV, Leong T, Roche PC, et al. Prognostic value of bone marrow angiogenesis in multiple myeloma. Clin Cancer Res 2000;6:3111–3116.
   PubMed Web of Science ®Google Scholar
• Suyani E, Sucak GT, Akyurek N, et al. Tumor-associated macrophages as a prognostic parameter in multiple myeloma. Ann Hematol2013 Jan 20. [Epub ahead of print]
   Google Scholar
• Lin EY, Pollard JW. Tumor-associated macrophages press the angiogenic switch in breast cancer. Cancer Res 2007;67:5064–5066.
   PubMed Web of Science ®Google Scholar
• Lewis JS, Landers RJ, Underwood JC, et al. Expression of vascular endothelial growth factor by macrophages is up-regulated in poorly vascularized areas of breast carcinomas. J Pathol 2000;192:150–158.
   PubMed Web of Science ®Google Scholar
• Vacca A, Ria R, Ribatti D, et al. A paracrine loop in the vascular endothelial growth factor pathway triggers tumor angiogenesis and growth in multiple myeloma. Haematologica 2003;88:176–185.
   PubMed Web of Science ®Google Scholar
• Ribatti D, Nico B, Vacca A. Importance of the bone marrow microenvironment in inducing the angiogenic response in multiple myeloma. Oncogene 2006;25:4257–4266.
   PubMed Web of Science ®Google Scholar
• Sessa WC. Molecular control of blood flow and angiogenesis: role of nitric oxide. J Thromb Haemost 2009;7(Suppl. 1):35–37.
   PubMed Web of Science ®Google Scholar
• Ria R, Reale A, De Luisi A, et al. Bone marrow angiogenesis and progression in multiple myeloma. Am J Blood Res 2011;1:76–89.
   PubMedGoogle Scholar
• Galli SJ, Borregaard N, Wynn TA. Phenotypic and functional plasticity of cells of innate immunity: macrophages, mast cells and neutrophils. Nat Immunol 2011;12:1035–1044.
   PubMed Web of Science ®Google Scholar
• Ribatti D, Crivellato E. Mast cells, angiogenesis, and tumour growth. Biochim Biophys Acta 2012;1822:2–8.
   PubMed Web of Science ®Google Scholar
• Ribatti D, Crivellato E, Molica S. Mast cells and angiogenesis in haematological malignancies. Leuk Res 2009;33:876–879.
   PubMed Web of Science ®Google Scholar
• Vacca A, Ribatti D. Angiogenesis and vasculogenesis in multiple myeloma: role of inflammatory cells. Recent Results Cancer Res 2011;183:87–95.
   PubMedGoogle Scholar
• Scavelli C, Nico B, Cirulli T, et al. Vasculogenic mimicry by bone marrow macrophages in patients with multiple myeloma. Oncogene 2008;27:663–674.
   PubMed Web of Science ®Google Scholar
• Moschetta M, Di Pietro G, Ria R, et al. Bortezomib and zoledronic acid on angiogenic and vasculogenic activities of bone marrow macrophages in patients with multiple myeloma. Eur J Cancer 2010;46:420–429.
   PubMed Web of Science ®Google Scholar
• Kim D, Wang J, Willingham SB, et al. Anti-CD47 antibodies promote phagocytosis and inhibit the growth of human myeloma cells. Leukemia 2012;26:2538–2545.
   PubMed Web of Science ®Google Scholar
• Chao MP, Weissman IL, Majeti R. The CD47-SIRPalpha pathway in cancer immune evasion and potential therapeutic implications. Curr Opin Immunol 2012;24:225–232.
   PubMed Web of Science ®Google Scholar
• Podar K, Chauhan D, Anderson KC. Bone marrow microenvironment and the identification of new targets for myeloma therapy. Leukemia 2009;23:10–24.
   PubMed Web of Science ®Google Scholar
• Ramasamy R, Lam EW, Soeiro I, et al. Mesenchymal stem cells inhibit proliferation and apoptosis of tumor cells: impact on in vivo tumor growth. Leukemia 2007;21:304–310.
   PubMed Web of Science ®Google Scholar
• Karnoub AE, Dash AB, Vo AP, et al. Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature 2007;449:557–563.
   PubMed Web of Science ®Google Scholar
• Markovina S, Callander NS, O’Connor SL, et al. Bone marrow stromal cells from multiple myeloma patients uniquely induce bortezomib resistant NF-kappaB activity in myeloma cells. Mol Cancer 2010;9:176.
   PubMed Web of Science ®Google Scholar
• Carter A, Merchav S, Silvian-Draxler I, et al. The role of interleukin-1 and tumour necrosis factor-alpha in human multiple myeloma. Br J Haematol 1990;74:424–431.
   PubMed Web of Science ®Google Scholar
• Uchiyama H, Barut BA, Mohrbacher AF, et al. Adhesion of human myeloma-derived cell lines to bone marrow stromal cells stimulates interleukin-6 secretion. Blood 1993;82:3712–3720.
   PubMed Web of Science ®Google Scholar
• Nefedova Y, Landowski TH, Dalton WS. Bone marrow stromal-derived soluble factors and direct cell contact contribute to de novo drug resistance of myeloma cells by distinct mechanisms. Leukemia 2003;17:1175–1182.
   PubMed Web of Science ®Google Scholar
• Xie JY, Li MX, Xiang DB, et al. Elevated expression of APE1/Ref-1 and its regulation on IL-6 and IL-8 in bone marrow stromal cells of multiple myeloma. Clin Lymphoma Myeloma Leuk 2010;10:385–393.
   PubMed Web of Science ®Google Scholar
• Sanz-Rodriguez F, Ruiz-Velasco N, Pascual-Salcedo D, et al. Characterization of VLA-4-dependent myeloma cell adhesion to fibronectin and VCAM-1. Br J Haematol 1999;107:825–834.
   PubMed Web of Science ®Google Scholar
• Michigami T, Shimizu N, Williams PJ, et al. Cell-cell contact between marrow stromal cells and myeloma cells via VCAM-1 and alpha(4)beta(1)-integrin enhances production of osteoclast-stimulating activity. Blood 2000;96:1953–1960.
   PubMed Web of Science ®Google Scholar
• Anton K, Banerjee D, Glod J. Macrophage-associated mesenchymal stem cells assume an activated, migratory, pro-inflammatory phenotype with increased IL-6 and CXCL10 secretion. PLoS One 2012;7:e35036.
   PubMed Web of Science ®Google Scholar
• Kim J, Hematti P. Mesenchymal stem cell-educated macrophages: a novel type of alternatively activated macrophages. Exp Hematol 2009;37:1445–1453.
   PubMed Web of Science ®Google Scholar
• Roca H, Varsos ZS, Sud S, et al. CCL2 and interleukin-6 promote survival of human CD11b+ peripheral blood mononuclear cells and induce M2-type macrophage polarization. J Biol Chem 2009;284: 34342–34354.
   PubMed Web of Science ®Google Scholar
• Balkwill F. Tumour necrosis factor and cancer. Nat Rev Cancer 2009;9:361–371.
   PubMed Web of Science ®Google Scholar
• Balkwill F, Joffroy C. TNF: a tumor-suppressing factor or a tumor-promoting factor?. Future Oncol 2010;6:1833–1836.
   PubMed Web of Science ®Google Scholar
• Cordero JB, Macagno JP, Stefanatos RK, et al. Oncogenic Ras diverts a host TNF tumor suppressor activity into tumor promoter. Dev Cell 2010;18:999–1011.
   PubMed Web of Science ®Google Scholar
• Chapman MA, Lawrence MS, Keats JJ, et al. Initial genome sequencing and analysis of multiple myeloma. Nature 2011;471: 467–472.
   PubMed Web of Science ®Google Scholar
• Zhang QZ, Su WR, Shi SH, et al. Human gingiva-derived mesenchymal stem cells elicit polarization of M2 macrophages and enhance cutaneous wound healing. Stem Cells 2010;28: 1856–1868.
   PubMed Web of Science ®Google Scholar
• Maggini J, Mirkin G, Bognanni I, et al. Mouse bone marrow-derived mesenchymal stromal cells turn activated macrophages into a regulatory-like profile. PLoS One 2010;5:e9252.
   PubMed Web of Science ®Google Scholar
• Guilloton F, Caron G, Menard C, et al. Mesenchymal stromal cells orchestrate follicular lymphoma cell niche through the CCL2-dependent recruitment and polarization of monocytes. Blood 2012;119:2556–2567.
   PubMed Web of Science ®Google Scholar
• Ren G, Zhao X, Wang Y, et al. CCR2-dependent recruitment of macrophages by tumor-educated mesenchymal stromal cells promotes tumor development and is mimicked by TNFalpha. Cell Stem Cell 2012;11:812–824.
   PubMed Web of Science ®Google Scholar
• Mantovani A. MSCs, macrophages, and cancer: a dangerous menage-a-trois. Cell Stem Cell 2012;11:730–732.
   PubMed Web of Science ®Google Scholar
• Kyle RA, Rajkumar SV. Treatment of multiple myeloma: a comprehensive review. Clin Lymphoma Myeloma 2009;9:278–288.
   PubMedGoogle Scholar
• Moreau P, Richardson PG, Cavo M, et al. Proteasome inhibitors in multiple myeloma: 10 years later. Blood 2012;120:947–959.
   PubMed Web of Science ®Google Scholar
• Quach H, Ritchie D, Stewart AK, et al. Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma. Leukemia 2010;24:22–32.
   PubMed Web of Science ®Google Scholar
• Zhu YX, Kortuem KM, Stewart AK. Molecular mechanism of action of immune-modulatory drugs thalidomide, lenalidomide and pomalidomide in multiple myeloma. Leuk Lymphoma2012 Sep 28. [Epub ahead of print]
   Google Scholar
• Mitsiades CS. How “immunomodulatory” are IMIDs?. Blood 2011;117:1440–1441.
   Google Scholar
• Hsu AK, Quach H, Tai T, et al. The immunostimulatory effect of lenalidomide on NK-cell function is profoundly inhibited by concurrent dexamethasone therapy. Blood 2011;117:1605–1613.
   PubMed Web of Science ®Google Scholar
• Corral LG, Kaplan G. Immunomodulation by thalidomide and thalidomide analogues. Ann Rheum Dis 1999;58(Suppl. 1):I107–I113.
   PubMed Web of Science ®Google Scholar
• Muller GW, Chen R, Huang SY, et al. Amino-substituted thalidomide analogs: potent inhibitors of TNF-alpha production. Bioorg Med Chem Lett 1999;9:1625–1630.
   PubMed Web of Science ®Google Scholar
• Krishnan A, Pasquini MC, Logan B, et al. Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial. Lancet Oncol 2011;12:1195–1203.
   PubMed Web of Science ®Google Scholar
• Sato T, Terai M, Tamura Y, et al. Interleukin 10 in the tumor microenvironment: a target for anticancer immunotherapy. Immunol Res 2011;51:170–182.
   PubMed Web of Science ®Google Scholar
• Serebrennikova OB, Tsatsanis C, Mao C, et al. Tpl2 ablation promotes intestinal inflammation and tumorigenesis in Apcmin mice by inhibiting IL-10 secretion and regulatory T-cell generation. Proc Natl Acad Sci USA 2012;109:E1082–E1091.
   PubMed Web of Science ®Google Scholar
• Ni Y, Gopalsamy A, Cole D, et al. Identification and SAR of a new series of thieno[3,2-d]pyrimidines as Tpl2 kinase inhibitors. Bioorg Med Chem Lett 2011;21:5952–5956.
   PubMed Web of Science ®Google Scholar
• Teli MK, Rajanikant GK. Pharmacophore generation and atom-based 3D-QSAR of novel quinoline-3-carbonitrile derivatives as Tpl2 kinase inhibitors. J Enzyme Inhib Med Chem 2012;27:558–570.
   PubMed Web of Science ®Google Scholar
• Hu Y, Cole D, Denny RA, et al. Discovery of indazoles as inhibitors of Tpl2 kinase. Bioorg Med Chem Lett 2011;21:4758–4761.
   PubMed Web of Science ®Google Scholar
• Wu J, Green N, Hotchandani R, et al. Selective inhibitors of tumor progression loci-2 (Tpl2) kinase with potent inhibition of TNF-alpha production in human whole blood. Bioorg Med Chem Lett 2009;19:3485–3488.
   PubMed Web of Science ®Google Scholar
• Cusack K, Allen H, Bischoff A, et al. Identification of a selective thieno[2,3-c]pyridine inhibitor of COT kinase and TNF-alpha production. Bioorg Med Chem Lett 2009;19:1722–1725.
   PubMed Web of Science ®Google Scholar
• Hall JP, Kurdi Y, Hsu S, et al. Pharmacologic inhibition of tpl2 blocks inflammatory responses in primary human monocytes, synoviocytes, and blood. J Biol Chem 2007;282:33295–33304.
   PubMed Web of Science ®Google Scholar
• Kaila N, Green N, Li HQ, et al. Identification of a novel class of selective Tpl2 kinase inhibitors: 4-alkylamino-[1,7]naphthyridine-3-carbonitriles. Bioorg Med Chem 2007;15:6425–6442.
   PubMed Web of Science ®Google Scholar
• Luciano BS, Hsu S, Channavajhala PL, et al. Phosphorylation of threonine 290 in the activation loop of Tpl2/Cot is necessary but not sufficient for kinase activity. J Biol Chem 2004;279:52117–52123.
   PubMed Web of Science ®Google Scholar
• Green N, Hu Y, Janz K, et al. Inhibitors of tumor progression loci-2 (Tpl2) kinase and tumor necrosis factor alpha (TNF-alpha) production: selectivity and in vivo antiinflammatory activity of novel 8-substituted-4-anilino-6-aminoquinoline-3-carbonitriles. J Med Chem 2007;50:4728–4745.
   PubMed Web of Science ®Google Scholar
• Kim JE, Son JE, Jang YJ, et al. Luteolin, a novel natural inhibitor of tumor progression locus 2 serine/threonine kinase, inhibits tumor necrosis factor-alpha-induced cyclooxygenase-2 expression in JB6 mouse epidermis cells. J Pharmacol Exp Ther 2011;338:1013–1022.
   PubMed Web of Science ®Google Scholar
• Dumitru CD, Ceci JD, Tsatsanis C, et al. TNF-alpha induction by LPS is regulated posttranscriptionally via a Tpl2/ERK-dependent pathway. Cell 2000;103:1071–1083.
   PubMed Web of Science ®Google Scholar
• Majeti R, Chao MP, Alizadeh AA, et al. CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells. Cell 2009;138:286–299.
   PubMed Web of Science ®Google Scholar
• Conti I, Rollins BJ. CCL2 (monocyte chemoattractant protein-1) and cancer. Semin Cancer Biol 2004;14:149–154.
   PubMed Web of Science ®Google Scholar
• Qian BZ, Li J, Zhang H, et al. CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis. Nature 2011;475: 222–225.
   PubMed Web of Science ®Google Scholar
• Struthers M, Pasternak A. CCR2 antagonists. Curr Top Med Chem 2010;10:1278–1298.
   PubMed Web of Science ®Google Scholar
• Otjacques E, Binsfeld M, Noel A, et al. Biological aspects of angiogenesis in multiple myeloma. Int J Hematol 2011;94:505–518.
   PubMed Web of Science ®Google Scholar
• Pellegrino A, Ria R, Di Pietro G, et al. Bone marrow endothelial cells in multiple myeloma secrete CXC-chemokines that mediate interactions with plasma cells. Br J Haematol 2005;129:248–256.
   PubMed Web of Science ®Google Scholar
• Germano G, Frapolli R, Belgiovine C, et al. Role of macrophage targeting in the antitumor activity of trabectedin. Cancer Cell 2013;23:249–262.
   PubMed Web of Science ®Google Scholar